Breaking News

New CWRU study targets suicide risk among LGBTQ+ youth in Cleveland’s child welfare, juvenile justice systems

Architect: Here’s How to Build Homes in Fire-Prone Areas

Study reveals biomarker for high risk of metastasis

BLACK HOLES CAN COOK FOR THEMSELVES, CHANDRA STUDY SHOWS

Weight-Loss Surgery Lowers Risk of Developing Complications of Liver Disease in Patients with Cirrhosis and Obesity

Study Results: Exploring Gastric Cancer Risk Through Oral Microbiomes

Children’s Hospital Los Angeles Adds Transformative Gene Therapy and Expands to 10 Treatments, Becoming the Largest Provider of Pediatric Cell and Gene Therapies on the West Coast

Cancer risk established before birth

For Osteoarthritis Patients, Radiation Can Bring Winter Weather Relief

The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine Selected as a U.S. Site for Neuralink Clinical Trial

28 Jan, 2025

ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.

May 29, 2024 sarah JonasResearch Alert

Post Views: 163

For this presentation at ASCO 2024, please email the media contact for more information.

withyou android app